SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-18-004349
Filing Date
2018-05-08
Accepted
2018-05-08 17:15:48
Documents
70
Period of Report
2018-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q acrs-20180331x10q.htm 10-Q 1564073
2 EX-10.1 acrs-20180331ex1016d3773.htm EX-10.1 245511
3 EX-31.1 acrs-20180331ex31123969c.htm EX-31.1 17114
4 EX-31.2 acrs-20180331ex312a28cc3.htm EX-31.2 17100
5 EX-32.1 acrs-20180331ex321933e79.htm EX-32.1 10647
  Complete submission text file 0001558370-18-004349.txt   6858351

Data Files

Seq Description Document Type Size
6 EX-101.INS acrs-20180331.xml EX-101.INS 1561180
7 EX-101.SCH acrs-20180331.xsd EX-101.SCH 42315
8 EX-101.CAL acrs-20180331_cal.xml EX-101.CAL 50549
9 EX-101.DEF acrs-20180331_def.xml EX-101.DEF 139675
10 EX-101.LAB acrs-20180331_lab.xml EX-101.LAB 452774
11 EX-101.PRE acrs-20180331_pre.xml EX-101.PRE 305641
Mailing Address SUITE 400, 101 LINDENWOOD DRIVE MALVERN PA 19355
Business Address SUITE 400, 101 LINDENWOOD DRIVE MALVERN PA 19355 484-321-5554
Aclaris Therapeutics, Inc. (Filer) CIK: 0001557746 (see all company filings)

IRS No.: 460571712 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-37581 | Film No.: 18815772
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences